RESULTS PREVIEW

Capital Goods

Fair value: SEK47.0–65.0

Share price: SEK55.6

Svedbergs Group

Expect no signs of improving markets – Q2 preview

Research analysts:
Markus Almerud
DNB Carnegie Investment Bank AB

While we do not expect any improvement in demand for Q2, we still forecast continued improvement in the organic growth trend – albeit at low levels. Improvement in Svedbergs brand's margin is a key driver of the group margin and continuous improvement is a focus in the report. Our EBITA estimates are broadly unchanged, and we have adjusted our fair value to SEK47–65 (51–72).

Looking for organic growth of 3%... We have seen few signs of any improvement in the markets – the consumer remains subdued. For growth to accelerate, we believe we need to see the transaction market take off. We expect the positive trend to continue (albeit at low levels) and forecast 3% organic growth. We expect Rhoper Rhodes to continue to gain market share.

…and for the margin to almost reach 15%. With some extra personnel costs in Rhoper Rhodes and some projects in Sweden that did not repeat in Q2, we expect the margin to be slightly below Q1 at 14.9%. We believe Svedbergs' brand is key to the margin taking off. It has traditionally had a larger share of projects than the other parts of the group, and hence it has a higher fixed cost base and operational leverage. For it to get back to high-teens margins, we believe volumes must return. Nevertheless, with a lower cost base, we believe it can reach double-digit margins even at no volume growth. Management believes it can reach this level by Q4.

Will look for any signs of the Swedish market improving. Except to to get confirmation that the margin trend in the Svedbergs brand continues, we will look for any signs of the Swedish markets improving in the Q2 report. Continuous market share gains in the UK will also be in focus – it is important, as it is the largest share of the group.

Estimates largely unchanged. We have made marginal changes to our EBITA (-1% for 2025e and no changes for 2026–27e), but did change the definition of adj. EPS (it no longer includes PPA), which lowers adj. EPS. We have adjusted our fair value to SEK47–65 (51–72).

Changes in this report	From	To	Chg
EPS adj. 2025e	4.0	3.7	-8%
EPS adj. 2026e	4.5	4.2	-7%
EPS adj. 2027e	4.9	4.6	-6%

Upcoming events	
Q2 Report	18 Jul 2025
Q3 Report	29 Oct 2025

Key facts	
No. shares (m)	53.0
Market cap. (USDm)	309
Market cap. (SEKm)	2,946
Net IB Debt. (SEKm)	609
Adjustments (SEKm)	0
EV (2025e) (SEKm)	3,555
Free float	55.9%
Avg. daily vol. ('000)	29
BBG	SVEDB SS
Fiscal year end	December
Share price as of (CET)	14 Jul 2025 15:59

Key figures (SEK)	2024	2025e	2026e	2027e
Sales (m)	2,184	2,217	2,302	2,404
EBITDA (m)	374	394	424	451
EBIT (m)	296	314	341	364
EPS	3.25	3.68	4.17	4.59
EPS adj.	3.26	3.68	4.17	4.59
DPS	1.50	1.75	2.00	2.30
Sales growth Y/Y	20%	2%	4%	4%
EPS adj. growth Y/Y	-13%	13%	13%	10%
EBIT margin	13.6%	14.2%	14.8%	15.2%
P/E adj.	17.1	15.1	13.3	12.1
EV/EBIT	9.9	11.3	10.1	9.1
EV/EBITA	9.4	10.8	9.6	8.7
EV/EBITDA	7.8	9.0	8.1	7.3
P/BV	1.9	1.8	1.7	1.6
Dividend yield	2.7%	3.1%	3.6%	4.1%
FCF yield	3.6%	7.3%	7.9%	8.6%
Equity/Total Assets	49.0%	53.1%	56.8%	60.5%
ROCE	13.2%	11.9%	13.0%	14.0%
ROE adj.	13.4%	12.3%	13.1%	13.5%
Net IB debt/EBITDA	2.0	1.5	1.1	0.8

Share price – 5-year

High/Low (12M)				SEK56.6/39.5
Perf.	3M	6M	12M	YTD
Abs.	17.42	39.52	18.30	34.14
Rel.	7.85	37.72	22.17	32.16

Source: DNB Carnegie (estimates), FactSet, Infront & company data

Equity story

Near term: within 12M

We believe that the bottom of the housing construction market, both in terms of newbuilds and renovations, is behind us and that it will not get worse from here. The timing and strength of the recovery, however, are unclear. Currently, we expect a gradual recovery in 2025.

Long-term outlook: 5Y+

The shortage of housing should drive growth in bathroom installations over time. We expect mid-single-digit market growth in the medium to long term for the European bathroom furniture market.

Key risks:

- The housing market does not recover.
- The economic downcycle is prolonged.
- The Svedbergs brand is not able to recover its margin to historical levels.
- Acquisitions develop worse than expected.
- The company is not able to find suitable targets.

Company description

Svedbergs Group designs and manufactures bathroom interiors and products. The company offers a comprehensive range of bathroom items, including furniture, washbasins, mixers, showers, heated towel rails, and WCs, among others. The group operates through subsidiaries Svedbergs, Macro Design, Cassoe, Roper Rhodes and Thebalux. Its strategy is to grow by acquiring independent innovative and sustainable brands that complement its geographic presence or portfolio.

Key industry drivers

- Housing renovations
- New housing construction

Industry outlook

- We believe that the construction market, both new and renovation, has troughed
- We expect a slow recovery in the coming years

Largest shareholders, capital

Stena Adactum	43.0%
Nordea Funds	14.6%
If Skadeförsäkring AB	11.5%

Cyclicality

Cyclicality: Yes

Late

Key peers

FM Mattsson, Ifö, Gustavsberg, Inwido, Balco Group, Nordic Waterproofing.

Valuation and methodology

Our fair value range is based on upside and downside potential scenarios applied to multiples-based valuations. We use a P/E of 13x and an EV/EBITA of 11x on our 2026 estimates and discount the values back to today. Peers are trading at average P/E (2026e) of 11x and EV/EBITA (2026e) of 11x. Given Svedberg Group's solid balance sheet, we believe it is fair that it trades at a higher P/E than the peer group.

Fair value range 12M



Our downside scenario is based on a 3-year sales CAGR of 1% and EBITA CAGR of 2%, while our upside scenario is based on 3-year sales CAGR of 6% and EBITA CAGR of 12%.

Key metrics



P/E 12-months forward



Long-term valuation trend



Source: DNB Carnegie (estimates) & company data

Svedbergs Group in key charts

The acquisitions of Roper Rhodes in the UK and Thebalux in the Netherlands have driven sales of the group…

Svedbergs Group sales (SEKbn)



Source: Company data

… and now Sweden accounts for less than one-fifth of sales compared with 76% in 2016

Svedbergs Group geographical sales split (2024)



Source: Company data

We expect the organic growth trend to continue to improve

Svedbergs Group organic growth



Source: DNB Carnegie (estimates) & Company data

As the margin in Svedbergs (brand) part of the group recovers, the group margin should keep improving

Svedbergs Group sales and EBITA margin



Source: DNB Carnegie (estimates) & Company data

Valuation and risks

Our fair value range is based on upside and downside potential scenarios applied to multiples-based valuations. Based on our estimates, we arrive at a fair value range of SEK47–65.

Svedbergs Group FV range (SEK)



Source: DNB Carnegie

Assumptions

Our multiples-based approach returns values of SEK46–68 per share. We use a P/E of 13x and an EV/EBITA of 11x, to which we apply our 2026 estimates and discount the values back to today. Peers are trading at average 2026e P/Es of 11x and 2026e EV/EBITs of 11x. Given Svedberg's solid balance sheet, we believe it is fair that it trades at a higher P/E than EV/EBIT.

Our downside risk scenario is based on a 3-year sales CAGR of 1% and EBITA CAGR of 2%, while our upside potential scenario is based on a 3-year sales CAGR of 6% and EBITA CAGR of 12%.

Multiples-based calculations

P/E based			
2026 EPS (SEK)	3.7	4.2	4.9
P/E	13x	13x	13x
Value end of 2025 (SEK)	47	54	64
PV per share (SEK)	**46**	**52**	**62**
EV/EBITA based			
2026 EBITA (SEKm)	319	356	412
EV/EBITA	11x	11x	11x
EV end of 2025 (SEKbn)	3.5	3.9	4.5
Current EV (SEKbn)	3.4	3.8	4.4
Current net debt (SEKbn)	0.8	0.8	0.8
Equity value (SEKbn)	2.6	3.0	3.6
No shares (m)	52	53	53
Value per share (SEK)	**50**	**56**	**68**
Average (SEK)	**48**	**54**	**65**

Source: DNB Carnegie

Svedbergs peer group P/E 2026e



Source: Factset

Svedbergs peer group EV/EBITA 2026e



Source: Factset

Risks

Svedbergs faces several potential risks that could impact its operations and financial performance. Below we have outlined the risks that we consider to be the most significant for the company. Note that the list should not be considered exhaustive and is presented in no particular order.

- **Market and economic risks:** Demand for Svedberg's products depends on the broader economic climate, including interest rates, exchange rates, and unemployment rates. Economic slowdowns can reduce consumer spending on home improvements, directly impacting demand for bathroom products. Declines in housing transactions and new constructions can adversely affect sales, as fewer new bathrooms are installed.

- **Operational risks:** Dependence on suppliers for raw materials and finished products makes the company vulnerable to supply chain interruptions, which can affect production schedules and costs. As the group's growth strategy includes acquisitions, such as Thebalux, there is a risk that the acquired units will not perform as expected.

- **Strategic risks:** While M&A can drive growth, they also carry risks like overvaluation, integration difficulties, and diversion of management attention. Maintaining a premium brand image requires continuous innovation and quality assurance. Failure to do so could erode market share.

- **Regulatory and compliance risks:** The company must comply with environmental laws concerning production processes, waste management, and product materials. Non-compliance can lead to fines and reputational damage. Ensuring all products meet safety and quality standards is crucial. Any lapses can result in recalls and legal issues.

- **Technological risks:** The need to adopt new technologies for production, distribution, and customer engagement requires significant investment. Lagging in this area can lead to competitive disadvantages. As operations become more digitized, the risk of cyber-attacks increases, potentially compromising sensitive data and disrupting business activities.

Estimate changes

Svedbergs (SEKm, ex p share)	New est. 2025e	New est. 2026e	New est. 2027e	Old est. 2025e	Old est. 2026e	Old est. 2027e	Abs. Change 2025e	Abs. Change 2026e	Abs. Change 2027e	% change 2025e	% change 2026e	% change 2027e
Net sales	2,217	2,302	2,404	2,227	2,314	2,408	(10)	(12)	(3)	0%	-1%	0%
Growth	1.5%	3.9%	4.4%	2.0%	3.9%	4.0%	0 pp	0 pp	0 pp			
Organic	*3.9%*	*4.1%*	*4.0%*	*4.7%*	*4.1%*	*4.0%*	*-1 pp*	*0 pp*	*0 pp*			
Acq/div	*0.0%*	*0.0%*	*0.0%*	*0.0%*	*0.0%*	*0.0%*	*0 pp*	*0 pp*	*0 pp*			
Currency	*-2.4%*	*0.0%*	*0.4%*	*-2.8%*	*0.0%*	*0.0%*	*0 pp*	*0 pp*	*0 pp*			
Adj. EBITA	330	356	380	331	357	379	(2)	(1)	1	-1%	0%	0%
Margin	*14.9%*	*15.5%*	*15.8%*	*14.9%*	*15.4%*	*15.7%*	*0 pp*	*0 pp*	*0 pp*			
PPA	(16)	(16)	(16)	(16)	(16)	(16)	-	-	-	0%	0%	0%
EO	-	-	-	-	-	-	-	-	-	nm	nm	nm
EBIT	314	341	364	316	341	363	(2)	(1)	1	-1%	0%	0%
Net interest	(51)	(42)	(35)	(51)	(42)	(35)	-	0	0	0%	0%	0%
Pre tax profit	263	299	329	265	299	328	(2)	(0)	1	-1%	0%	0%
Tax	(68)	(78)	(86)	(69)	(78)	(85)	0	0	(0)	-1%	0%	0%
Net profit	195	221	243	196	221	243	(1)	(0)	1	-1%	0%	0%
EPS	3.7	4.2	4.6	3.7	4.2	4.6	(0.0)	(0.0)	0.0	-1%	0%	0%
EPS (adj)	3.7	4.2	4.6	4.0	4.5	4.9	(0.3)	(0.3)	(0.3)	-8%	-7%	-6%
DPS	1.8	2.0	2.3	1.8	2.0	2.3	-	-	0.0	0%	0%	0%
NIBD	609	483	353	610	484	352	(1)	(1)	1	0%	0%	0%
Segments												
Sales (SEKm)												
Svedbergs	389	407	427	407	427	448	(18)	(20)	(21)	-4%	-5%	-5%
Macro Design	172	179	186	172	179	186	-	-	-	0%	0%	0%
Cassoe	87	89	92	89	92	95	(2)	(2)	(3)	-3%	-3%	-3%
Roper Rhodes	1,154	1,196	1,248	1,144	1,185	1,228	10	11	20	1%	1%	2%
Thebalux	415	431	451	415	432	451	(0)	(0)	(0)	0%	0%	0%
EBITA Adj. (SEKm)												
Svedbergs	30	36	42	22	28	35	8	8	7	36%	27%	21%
Macro Design	23	25	26	19	20	22	4	4	4	23%	22%	20%
Cassoe	17	18	18	17	17	18	(0)	0	0	-1%	2%	2%
Roper Rhodes	207	220	230	221	233	242	(14)	(14)	(12)	-6%	-6%	-5%
Thebalux	94	100	105	95	100	104	(0)	1	1	0%	1%	1%
Other	(42)	(42)	(42)	(42)	(42)	(42)	-	-	-	0%	0%	0%

Source: DNB Carnegie

Interim figures

Svedberg											Full year est.				
(SEKm, ex p share)	2Q24	3Q24	4Q24	1Q25	2Q25e	3Q25e	4Q25e	1Q26e	2Q26e	3Q26e	2023	2024	2025e	2026e	2027e
Net sales	562	512	537	596	561	517	542	620	584	538	1,824	2,184	2,217	2,302	2,404
Growth	*23.4%*	*18.6%*	*16.8%*	*4.3%*	*-0.2%*	*0.9%*	*0.9%*	*3.9%*	*4.1%*	*4.1%*	*-0.5%*	*19.7%*	*1.5%*	*3.9%*	*4.4%*
Organic	*-1.6%*	*-1.4%*	*0.2%*	*3.5%*	*3.1%*	*4.0%*	*4.8%*	*4.0%*	*4.0%*	*4.1%*	*-6.2%*	*-1.7%*	*3.9%*	*4.1%*	*4.0%*
Acq/div	*23.4%*	*21.7%*	*14.3%*	*0.0%*	*0.0%*	*0.0%*	*0.0%*	*0.0%*	*0.0%*	*0.0%*	*2.1%*	*20.3%*	*0.0%*	*0.0%*	*0.0%*
Currency	*1.6%*	*-1.7%*	*2.3%*	*0.8%*	*-3.3%*	*-3.1%*	*-4.0%*	*-0.1%*	*0.0%*	*0.0%*	*3.7%*	*1.1%*	*-2.4%*	*0.0%*	*0.4%*
Adj. EBITA	76	71	81	94	84	75	77	100	93	79	240	312	330	356	380
Margin	*13.5%*	*13.9%*	*15.1%*	*15.7%*	*14.9%*	*14.6%*	*14.1%*	*16.1%*	*16.0%*	*14.8%*	*13.2%*	*14.3%*	*14.9%*	*15.5%*	*15.8%*
PPA	(4)	(4)	(4)	(4)	(4)	(4)	(4)	(4)	(4)	(4)	(11)	(16)	(16)	(16)	(16)
EO	-	-	-	-	-	-	-	-	-	-	(18)	(0)	-	-	-
EBIT	72	67	77	90	80	71	73	96	89	76	210	296	314	341	364
Net interest	(18)	(30)	(7)	(19)	(11)	(11)	(10)	(9)	(9)	(9)	(51)	(67)	(51)	(42)	(35)
Pre tax profit	54	38	71	71	69	60	63	87	80	67	160	229	263	299	329
Tax	(13)	(10)	(21)	(19)	(18)	(16)	(17)	(23)	(22)	(18)	(41)	(61)	(68)	(78)	(86)
Net profit	40	28	50	52	51	45	46	63	59	49	119	168	195	221	243
EPS	0.8	0.5	0.9	1.0	0.96	0.84	0.86	1.2	1.1	0.9	3.4	3.3	3.7	4.2	4.6
EPS (adj)	0.8	0.6	1.0	1.1	1.04	0.92	0.96	1.3	1.2	1.0	3.8	3.3	3.7	4.2	4.6
DPS											1.0	1.5	1.8	2.0	2.3
Segments															
Sales (SEKm)															
Svedbergs	102	76	102	108	100	76	105	112	105	80	480	393	389	407	427
Macro Design	44	35	45	44	45	36	46	46	47	37	163	165	172	179	186
Cassoe	25	19	21	23	22	19	22	24	23	19	88	87	87	89	92
Roper Rhodes	285	289	275	306	284	292	272	318	296	303	1,062	1,138	1,154	1,196	1,248
Thebalux	107	94	95	115	109	95	96	119	114	99	30	401	415	431	451
Adj. EBIT (SEKm)															
Svedbergs	1.3	1.3	5.9	7.5	7.0	6.1	9.4	9.0	10.0	6.4	58.2	16.7	30.0	36.3	42.4
Macro Design	4.1	2.8	5.2	6.2	6.3	4.3	6.5	6.5	6.7	4.6	12.4	16.2	23.3	24.7	26.1
Cassoe	5.0	3.4	3.7	4.7	4.3	3.2	4.4	4.8	4.7	3.5	17.8	16.5	16.5	17.6	18.2
Roper Rhodes	49.1	55.2	60.2	55.0	50.6	52.5	49.0	58.2	54.1	54.9	176.5	213.7	207.1	219.6	230.1
Thebalux	27.9	18.3	17.2	30.0	27.3	19.0	18.1	31.1	29.5	19.7	1.0	89.4	94.4	100.2	105.0
Other	(11.6)	(9.7)	(10.8)	(9.8)	(11.6)	(9.7)	(10.8)	(9.8)	(11.6)	(9.7)	(25.8)	(40.3)	(41.9)	(41.9)	(41.9)
Adj. EBITA margin															
Svedbergs	1.3%	1.7%	5.8%	6.9%	7.0%	8.0%	9.0%	8.0%	9.5%	8.0%	12.1%	4.2%	7.7%	8.9%	9.9%
Macro Design	9.4%	8.1%	11.6%	14.0%	14.0%	12.0%	14.0%	14.0%	14.2%	12.5%	7.6%	9.8%	13.6%	13.8%	14.1%
Cassoe	20.3%	18.3%	17.9%	20.3%	19.0%	17.0%	19.5%	20.3%	20.3%	18.0%	20.2%	19.1%	19.1%	19.7%	19.7%
Roper Rhodes	17.2%	19.1%	21.9%	18.0%	17.8%	18.0%	18.0%	18.3%	18.3%	18.1%	16.6%	18.8%	17.9%	18.4%	18.4%
Thebalux	26.1%	19.5%	18.0%	26.1%	25.0%	20.0%	18.9%	26.0%	26.0%	20.0%	3.4%	22.3%	22.8%	23.2%	23.3%

Source: DNB Carnegie (estimates) & Company data

Financial statements

Profit & loss (SEKm)	2018	2019	2020	2021	2022	2023	2024	2025e	2026e	2027e
Sales	622	609	649	869	1,833	1,824	2,184	2,217	2,302	2,404
COGS	-363	-351	-375	-502	-1,076	-1,028	-1,188	-1,193	-1,224	-1,270
Gross profit	**260**	**258**	**274**	**366**	**757**	**796**	**996**	**1,024**	**1,078**	**1,134**
Other income & costs	-182	-177	-184	-240	-467	-523	-622	-630	-655	-684
Share in ass. operations and JV	0	0	0	0	0	0	0	0	0	0
EBITDA	**77**	**80**	**90**	**127**	**290**	**273**	**374**	**394**	**424**	**451**
Depreciation PPE	-10	-11	-10	-11	-15	-16	-27	-24	-25	-26
Depreciation lease assets	-2	-3	-3	-5	-19	-23	-24	-24	-25	-26
Amortisation development costs	0	0	0	0	0	0	0	0	0	0
Amortisation other intangibles	-9	-9	-9	-10	-12	-12	-12	-15	-17	-18
Impairments / writedowns	0	0	0	0	0	0	0	0	0	0
EBITA	**56**	**58**	**68**	**101**	**244**	**222**	**312**	**330**	**356**	**380**
Amortization acquisition related	-1	-2	-2	-6	-9	-11	-16	-16	-16	-16
Impairment acquisition related	0	0	0	0	0	0	0	0	0	0
EBIT	**55**	**56**	**66**	**95**	**234**	**210**	**296**	**314**	**341**	**364**
Share in ass. operations and JV	0	0	0	0	0	0	0	0	0	0
Net financial items	-3	-3	-4	-15	-28	-51	-67	-51	-42	-35
of which interest income/expenses	-3	-3	-4	-15	-28	-51	-67	-51	-42	-35
of which interest on lease liabilities	0	0	0	0	0	0	0	0	0	0
of which other items	0	0	0	0	0	0	0	0	0	0
Pre-tax profit	**51**	**53**	**62**	**80**	**206**	**160**	**229**	**263**	**299**	**329**
Taxes	-11	-12	-14	-21	-40	-41	-61	-68	-78	-86
Post-tax minorities interest	0	0	0	0	0	0	0	0	0	0
Discontinued operations	0	0	0	0	0	0	0	0	0	0
Net profit	**41**	**41**	**48**	**59**	**166**	**119**	**168**	**195**	**221**	**243**
Adjusted EBITDA	79	80	100	146	298	291	375	394	424	451
Adjusted EBITA	58	58	78	119	251	240	312	330	356	380
Adjusted EBIT	57	56	76	114	242	229	297	314	341	364
Adjusted net profit	42	41	56	73	171	133	168	195	221	243
Sales growth Y/Y	-2.7%	-2.1%	6.6%	33.8%	111.0%	-0.5%	19.7%	1.5%	3.9%	4.4%
EBITDA growth Y/Y	-7.3%	3.7%	12.4%	41.0%	128.7%	-6.0%	37.2%	5.1%	7.6%	6.4%
EBITA growth Y/Y	-12.8%	3.7%	16.9%	48.3%	142.1%	-9.1%	40.7%	5.7%	8.2%	6.6%
EBIT growth Y/Y	-13.2%	2.7%	17.9%	43.7%	146.5%	-10.2%	40.8%	6.0%	8.6%	6.9%
EBITDA margin	12.4%	13.2%	13.9%	14.6%	15.8%	15.0%	17.1%	17.8%	18.4%	18.7%
EBITA margin	9.0%	9.5%	10.5%	11.6%	13.3%	12.2%	14.3%	14.9%	15.5%	15.8%
EBIT margin	8.8%	9.2%	10.2%	10.9%	12.8%	11.5%	13.6%	14.2%	14.8%	15.2%
Tax rate	20.6%	22.4%	22.4%	26.1%	19.7%	25.6%	26.6%	26.0%	26.0%	26.0%

Cash flow (SEKm)	2018	2019	2020	2021	2022	2023	2024	2025e	2026e	2027e
EBITDA	77	80	90	127	290	273	374	394	424	451
Paid taxes	-16	0	-12	0	-30	-49	-66	-68	-78	-86
Change in NWC	-2	-17	18	-5	0	13	-76	-7	-18	-22
Interests paid	-6	-7	-8	-22	-24	-46	-57	-53	-45	-38
Actual lease payments	0	-2	0	0	-17	-23	-23	-24	-25	-26
Non cash adjustments	0	0	0	0	0	0	0	0	0	0
Discontinued operations	0	0	0	0	0	0	0	0	0	0
Total operating activities	**55**	**58**	**94**	**96**	**223**	**173**	**166**	**243**	**260**	**282**
Capex tangible assets	-11	-21	-18	-6	-14	-12	-51	-13	-14	-14
Capitalised development costs	-6	-5	-9	-7	-9	-11	-7	-14	-15	-15
Capex - other intangible assets	-1	0	0	-1	-7	-3	-3	0	0	0
Acquisitions/divestments	0	0	-57	-788	-149	-477	0	0	0	0
Other non-cash adjustments	0	0	0	0	0	0	0	0	0	0
Total investing activities	**-18**	**-26**	**-84**	**-803**	**-179**	**-502**	**-60**	**-27**	**-28**	**-30**
Dividend paid and received	-48	-26	0	-26	0	-53	-53	-93	-106	-122
Share issues & buybacks	0	0	0	0	480	0	391	0	0	0
Change in bank debt	15	8	12	992	-655	407	-445	-159	-126	-130
Other cash flow items	1	1	1	2	0	0	0	0	0	0
Total financing activities	**-32**	**-17**	**12**	**968**	**-176**	**354**	**-107**	**-251**	**-232**	**-252**
Operating cash flow	55	58	94	96	223	173	166	243	260	282
Free cash flow	37	32	67	82	193	147	106	216	232	252
Net cash flow	5	15	22	261	-131	24	-1	-36	0	0
Change in net IB debt	-10	7	7	-736	534	-390	462	123	126	130
Capex / Sales	1.8%	3.4%	2.8%	0.7%	0.7%	0.6%	2.3%	0.6%	0.6%	0.6%
NWC / Sales	22.6%	24.6%	23.2%	23.5%	17.1%	21.2%	20.3%	21.4%	21.2%	21.1%

Source: DNB Carnegie (estimates) & company data

Financial statements, cont.

Balance sheet (SEKm)	2018	2019	2020	2021	2022	2023	2024	2025e	2026e	2027e
Acquired intangible assets	114	114	162	485	614	838	886	886	886	886
Other fixed intangible assets	46	46	98	503	388	543	559	542	524	506
Capitalised development	0	0	0	0	0	0	0	0	0	0
Tangible assets	70	75	71	282	289	379	422	411	399	387
Lease assets	0	9	9	40	28	82	88	88	88	88
Other IB assets (1)	0	0	0	0	0	0	0	0	0	0
Other non-IB assets	0	0	0	0	2	3	5	5	5	5
Fixed assets	**231**	**245**	**341**	**1,311**	**1,320**	**1,845**	**1,959**	**1,931**	**1,902**	**1,872**
Inventories (2)	118	134	130	342	444	499	559	567	589	615
Receivables (2)	126	120	138	322	291	296	295	299	311	324
Prepaid exp. & other NWC items (2)	5	5	7	66	16	44	35	35	36	38
IB current assets (1)	0	0	0	0	0	0	0	0	0	0
Other current assets	7	0	0	2	19	21	38	38	38	38
Cash & cash equivalents (1)	21	36	58	320	200	217	236	200	200	200
Current assets	**277**	**296**	**334**	**1,051**	**971**	**1,076**	**1,162**	**1,139**	**1,174**	**1,215**
Total assets	**508**	**541**	**674**	**2,362**	**2,291**	**2,921**	**3,121**	**3,071**	**3,076**	**3,087**
Shareholders' equity	163	179	227	267	935	979	1,530	1,632	1,747	1,868
Minorities	0	0	0	0	0	0	0	0	0	0
Other equity	0	0	0	0	0	0	0	0	0	0
Total equity	**163**	**179**	**227**	**267**	**935**	**979**	**1,530**	**1,632**	**1,747**	**1,868**
Deferred tax	17	21	36	173	132	174	194	194	194	194
LT IB debt (1)	131	132	132	528	563	490	645	486	360	230
Other IB provisions (1)	0	0	0	0	0	0	0	0	0	0
Lease libilities	0	3	4	20	10	64	61	61	61	61
Other non-IB liabilities	0	0	25	163	164	187	5	5	5	5
LT liabilities	**148**	**156**	**196**	**884**	**868**	**915**	**905**	**746**	**621**	**490**
ST IB debt (1)	86	93	105	718	61	576	233	233	233	233
Payables (2)	43	37	39	102	113	161	183	185	192	201
Accrued exp. & other NWC items (2)	65	64	94	362	279	263	234	238	247	258
Other ST non-IB liabilities	3	3	6	5	3	5	5	5	5	5
Liabilities - assets held for sale	0	0	0	0	0	0	0	0	0	0
Current liabilities	**197**	**206**	**251**	**1,211**	**487**	**1,027**	**686**	**692**	**709**	**728**
Total equity and liabilities	**508**	**541**	**674**	**2,362**	**2,291**	**2,921**	**3,121**	**3,071**	**3,076**	**3,087**
Net IB debt (=1)	195	198	188	966	453	931	732	609	483	353
Net working capital (NWC) (=2)	142	159	143	265	360	414	471	479	497	519
Capital employed (CE)	397	434	509	1,725	1,720	2,301	2,691	2,635	2,624	2,615
Capital invested (CI)	372	404	484	1,576	1,678	2,256	2,426	2,405	2,394	2,385
Equity / Total assets	32%	33%	34%	11%	41%	34%	49%	53%	57%	61%
Net IB debt / EBITDA	2.5	2.5	2.1	7.6	1.6	3.4	2.0	1.5	1.1	0.8

Per share data (SEK)	2018	2019	2020	2021	2022	2023	2024	2025e	2026e	2027e
Adj. no. of shares in issue YE (m)	21.12	21.15	21.16	26.00	33.77	35.32	51.67	52.98	52.98	52.98
Diluted no. of Shares YE (m)	21.12	21.15	21.16	26.00	33.77	35.32	52.98	52.98	52.98	52.98
EPS	1.93	1.96	2.28	2.26	4.90	3.37	3.25	3.68	4.17	4.59
EPS adj.	2.00	1.96	2.64	2.79	5.07	3.75	3.26	3.68	4.17	4.59
CEPS	2.99	2.98	3.40	3.49	6.04	4.48	4.33	4.72	5.26	5.73
DPS	2.25	0.00	1.25	0.00	1.50	1.00	1.50	1.75	2.00	2.30
BVPS	7.71	8.46	10.7	10.3	27.7	27.7	28.9	30.8	33.0	35.3

Performance measures	2018	2019	2020	2021	2022	2023	2024	2025e	2026e	2027e
ROE	24.6%	24.3%	23.7%	23.8%	27.5%	12.4%	13.4%	12.3%	13.1%	13.5%
Adj. ROCE pre-tax	15.7%	15.1%	17.3%	11.3%	15.4%	12.7%	13.9%	12.5%	13.6%	14.6%
Adj. ROIC after-tax	12.4%	11.6%	13.6%	8.6%	12.4%	9.1%	9.8%	10.1%	11.0%	11.8%

Valuation	2018	2019	2020	2021	2022	2023	2024	2025e	2026e	2027e
FCF yield	1.2%	1.1%	2.3%	2.8%	6.6%	5.0%	3.6%	7.3%	7.9%	8.6%
Dividend yield YE	14.3%	0.0%	5.1%	0.0%	6.8%	3.2%	3.6%	3.1%	3.6%	4.1%
Dividend payout ratio	116.9%	0.0%	54.9%	0.0%	30.6%	29.7%	46.1%	47.6%	48.0%	50.0%
Dividend + buy backs yield YE	8.0%	0.0%	5.1%	0.0%	7.1%	4.8%	4.2%	3.6%	4.1%	4.5%
EV/Sales YE	0.85	0.89	1.09	2.96	0.66	1.11	1.34	1.60	1.49	1.37
EV/EBITDA YE	6.8	6.8	7.9	20.3	4.1	7.4	7.8	9.0	8.1	7.3
EV/EBITA YE	9.4	9.4	10.4	25.5	4.9	9.2	9.4	10.8	9.6	8.7
EV/EBITA adj. YE	9.1	9.4	9.1	21.5	4.8	8.5	9.4	10.8	9.6	8.7
EV/EBIT YE	9.6	9.7	10.7	27.0	5.1	9.7	9.9	11.3	10.1	9.1
P/E YE	8.2	8.3	10.8	27.3	4.5	9.3	12.7	15.1	13.3	12.1
P/E adj. YE	7.8	8.3	9.3	22.1	4.4	8.3	12.7	15.1	13.3	12.1
P/BV YE	2.04	1.94	2.29	6.02	0.80	1.13	1.44	1.81	1.69	1.58
Share price YE (SEK)	15.7	16.4	24.6	61.8	22.2	31.2	41.5	55.6		

Source: DNB Carnegie (estimates) & company data

Disclosures and disclaimers

DNB Carnegie

DNB Carnegie is a Business Area in the DNB Group comprising: 1) the investment services division of DNB Bank ASA; 2) DNB Carnegie Investment Bank AB (a wholly owned subsidiary of DNB Bank ASA); 3) DNB Markets, Inc. (a wholly owned subsidiary of DNB Bank ASA) and 4) Carnegie, Inc. (a wholly owned subsidiary of DNB Carnegie Investment Bank AB). DNB Carnegie is a leading, Nordic provider of investment services.

DNB Carnegie generates added value for institutions, companies and private clients in the areas of trading in securities, investment banking, and securities services.

The research of DNB Carnegie is produced in the investment services division of DNB Bank ASA and DNB Carnegie Investment Bank AB; thus “DNB Carnegie” should be read as meaning these two entities throughout the disclaimer text, unless otherwise expressively stated..

General

This research report has been prepared by DNB Carnegie and is based on information obtained from various public sources that DNB Carnegie believes to be reliable but has not independently verified, and DNB Carnegie makes no guarantee, representation or warranty as to its accuracy or completeness.

This research report does not, and does not attempt to, contain everything material that there is to be said about the company. Any opinions expressed herein reflect DNB Carnegie's judgement at the time this research report was prepared and are subject to change without notice.

DNB Bank ASA, its affiliates and subsidiaries, their directors, officers, shareholders, employees or agents, are not responsible for any errors or omissions, regardless of the cause, or for the results obtained from the use of this research report, and shall in no event be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs) in connection with any use of this research report.

Any use of non-DNB Carnegie logos in this research report is solely for the purpose of assisting in identifying the relevant party. DNB Carnegie is not affiliated with any such party.

DNB Carnegie produces and distributes research reports from 1) the investment services division of DNB Bank ASA; and 2) DNB Carnegie Investment Bank AB (a wholly owned subsidiary of DNB Bank ASA). Clients receiving research reports from DNB Carnegie will therefore receive research reports produced by both companies. This research report is produced in the DNB Carnegie company where the responsible analyst is employed, please see the responsible analyst's name and DNB Carnegie company on the front page under the analyst's name to determine in which DNB Carnegie company this research report is produced.

This research report is distributed in Norway, Singapore, Canada and Australia by the investment services division of DNB Bank ASA; in Sweden, Finland and Denmark by DNB Carnegie Investment Bank AB (a wholly owned subsidiary of DNB Bank ASA); and in the US and the UK by the investment services division of DNB Bank ASA and DNB Carnegie Investment Bank AB, respectively.

DNB Carnegie is under supervision

DNB Bank ASA is a bank incorporated in Norway and is authorised and regulated by the Norwegian Financial Supervisory Authority. DNB Bank ASA is established in Singapore and in the UK via its Singapore and UK branches, which are authorised and regulated by the Monetary Authority of Singapore, and on a limited basis by the Financial Conduct Authority and the Prudential Regulation Authority of the UK respectively. DNB Bank ASA is established in Sweden via its Sweden branch which are subject to supervision by the Financial Supervisory Authority of Sweden. DNB Carnegie Investment Bank AB is a bank incorporated in Sweden with limited liability and is authorised and regulated by the Swedish Financial Supervisory Authority. DNB Carnegie Investment Bank AB is established in the UK via its UK branch which is authorised and regulated by the UK Financial Conduct Authority (FCA). DNB Carnegie Investment Bank AB is established in Finland and Denmark via its Finland and Denmark branches which are subject to limited supervision by the respective national Supervisory Authorities.

Further details about the extent of regulation by local authorities outside Norway and Sweden are available on request.

Property rights

This research report is for clients only, and not for publication, and has been prepared for information purposes by DNB Carnegie.

This research report is the property of DNB Carnegie. DNB Carnegie retains all intellectual property rights (including, but not limited to, copyright) relating to this research report. Sell-side investment firms are not allowed any commercial use (including, but not limited to, reproduction and redistribution) of this research report contents, either partially or in full, without DNB Carnegie's explicit and prior written consent. However, buy-side investment firms may use this research report when making investment decisions, and may also base investment advice given to clients on this research report. Such use is dependent on the buy-side investment firm citing DNB Carnegie as the source.

The Report does not constitute investment advice

This research report is made for information purposes only, and does not constitute and should not in any way be considered as an offer to buy or sell any securities or other financial instruments or to participate in any investment strategy. This research report has been prepared as general information and is therefore not intended as a personal recommendation of particular financial instruments or strategies, and does not constitute personal investment advice. Investors should therefore make their own assessments of whether any of the trading ideas described herein are a suitable investment based on the investor's knowledge and experience, financial situation, and investment objectives.

Risk warning

The risk of investing in financial instruments is generally high. Past performance is not a reliable indicator of future performance, and estimates of future performance are based on assumptions that may not be realised. When investing in financial instruments, the value of the investment may increase or decrease, and the investor may lose all or part of their investment. Careful consideration of possible financial distress should be made before investing in any financial instrument.

Analyst certification

The research analyst(s) responsible for the content of this research report certify that: 1) the views expressed in this research report accurately reflect that research analyst's personal views about the company and the securities that are the subject of this research report; and 2) no part of the research analyst's compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by that research analyst in this research report. DNB Carnegie employees, including research analysts, may receive compensation that is generated by overall firm profitability.

Type of coverage, including valuation methodologies and assumptions

1. Fundamental analysis with a target price and recommendation. DNB Carnegie publishes a target price for most of the stocks in our Research Universe. The target price is the analyst's assessment of expected total return (including dividend per share) over the coming 12 months based on various fundamental valuation methods. The target price is based on a combination of several valuation methods such as discounted cash flow, pricing based on earnings multiples, multiple on book value, net asset value and peer comparison. A commonly used method is DCF valuation, where future cash flows are discounted to today. Analysts may also use different valuation multiples, e.g. P/E and EV/EBIT, relative to industry peers to obtain a target price. For companies where it is appropriate, a target price can also be based on the analyst's assessment of a fair ratio relative to the net asset value of the company. Target prices are revised when earnings and cash flow forecasts are changed. Thus, changes to estimates are a key risk to the target price. Other reasons for revising target prices include changes in the underlying value of a company's assets and when factors affecting the required rate of return change, which can also be seen as risk factors to the target price.

2. Quantitative and technical analysis. DNB Carnegie produces research based on quantitative and technical analysis (“quant products”). Such research is based on mathematical and technical models applied to companies, industries and sectors, rather than a fundamental analysis of a company. Quantitative and technical analysis thus does not result in estimates, a valuation or a recommendation (e.g. BUY, SELL, HOLD). Quant products may also have a significantly different time horizon from those of other products generated by DNB Carnegie. The views expressed in quant products may thus differ from, or conflict with, those presented in other research reports generated by DNB Carnegie.

3. Commissioned research reports include the analyst's assessment of a fair value range over the coming 6-12 months based on various fundamental valuation methods. A commonly used method is DCF valuation, where future cash flows are discounted to today. Analysts may also use different valuation multiples, e.g. P/E and EV/EBIT, relative to industry peers. For companies where it is appropriate, a fair value range can also be based on the analyst's assessment of a fair ratio relative to the net asset value of the company. Fair value ranges represent the assessment of the analyst(s) at the time of writing.

You will find detailed information about the valuation or methodology, the underlying assumptions, and risks on DNB Carnegie Edge (www.edge.carnegie.se). The complete history of equity research reports and previous recommendations can also be found on DNB Carnegie Edge and here.

Frequency of update

DNB Carnegie's research analysis consists of case-based analyses, meaning the frequency of the analytical research report may vary over time. Unless otherwise expressly stated in this research report, the analysis is updated when considered necessary by the research department, for example in the event of significant changes in market conditions or events related to the issuer/the financial instrument.

Potential conflicts of interest

DNB Carnegie may from time to time perform investment banking or other services for, or solicit investment banking or other business from, any company mentioned in this research report. Any such publicly announced business activity during the past 12 months will be referred to in the company-specific disclosures.

Readers should assume that any company mentioned in this research report may have an active client relationship with DNB Carnegie which is not disclosed due to client confidentiality e.g. trading in securities.

DNB Bank ASA, its affiliates and subsidiaries are engaged in commercial banking activities, and may for example be a lender to any company mentioned in this research report. This means that certain parts of these entities might have access to whatever rights and information regarding addressed companies as are available to a creditor under applicable law and the applicable loan and credit agreements.

DNB Carnegie and the rest of DNB Group have implemented a set of rules handling conflicts of interest. This includes confidentiality rules restricting the exchange of information between various parts of DNB Carnegie and the rest of DNB group. In order to restrict flows of sensitive information, appropriate information barriers have been established between the Investment Banking Division and other business departments in DNB Carnegie, and between DNB Carnegie and other business areas in the DNB Group. People outside an information barrier may gain access to sensitive information only after having observed applicable wall-crossing procedures. This means that employees of DNB Carnegie who are preparing the Reports are prevented from using or being aware of information available in other parts of DNB Carnegie or DNB Group that may be relevant to the recipients' decisions.

The remuneration of employees involved in preparing this research report is not tied to investment banking transactions performed by DNB Carnegie or a legal person within the same group.

Confidential and non-public information regarding DNB Carnegie and its clients, business activities and other circumstances that could affect the market value of a security ("sensitive information") is kept strictly confidential and may never be used in an undue manner. Internal guidelines are implemented to ensure the integrity and independence of research analysts. In accordance with the guidelines, the research department is separated from the Investment Banking department and there are no reporting lines between the research department and Investment Banking. The guidelines also include rules regarding, but not limited to, the following issues: contacts with covered companies, prohibition against offering favourable recommendations, personal involvement in covered companies, participation in investment banking activities, supervision and review of research reports, analyst reporting lines, and analyst remuneration.

DNB Carnegie and any of its officers or directors may have a position, or otherwise be interested in, transactions in securities that are directly or indirectly the subject of this research report. Any significant financial interests held by the analyst, DNB Carnegie, or a legal person in the same group in relation to the issuer will be referred to in the company-specific disclosures.

Other material conflicts of interest: Commissioned Research

This research report was commissioned and sponsored by the issuer (issuer-paid research) and should therefore be considered marketing communication (i.e. not investment research).

Payment for this research report has been agreed in advance on a non-recourse basis. As commissioned research, this research report can be considered an acceptable minor non-monetary benefit under MiFID II. It has not been prepared in accordance with the legal requirements designed to promote the independence of investment research. However, it is still subject to the same confidentiality rules and sound research principles.

Commissioned research is intended only for professional investors. Such investors are expected to make their own investment decisions without undue reliance on this research report.

Company specific disclosures

The following disclosures relate to relationships between DNB Carnegie Investment Bank AB (with its subsidiaries, "DNB Carnegie") and the subject company.

Please see edge.dnbcarnegie.se/legal/disclosuresanddisclaimers for equity disclosures and historical recommendation and target price information on all companies covered by DNB Carnegie.

Additional information for clients in Australia

This research report has been prepared and issued outside Australia.

DNB Bank ASA ARBN 675 447 702 is exempt from the requirement to hold an Australian financial services licence under the Corporations Act 2001 (Cth) ("Corporations Act") in respect of financial services it provides to "wholesale clients" within the meaning of the Corporations Act ("Wholesale Clients"). DNB Bank ASA accordingly does not hold an Australian financial services licence. DNB Bank ASA is regulated by Finanstilsynet (the Financial Supervisory Authority of Norway) under the laws of Norway, which differ from Australian laws.

This research report is provided only to authorised recipients who are both Wholesale Clients and "professional investors" within the meaning of the Corporations Act. In no circumstances may this research report be provided to any other person.

No member of the DNB Group, including DNB Bank ASA and DNB Carnegie Investment Bank AB, is an authorised deposit-taking institution ("ADI") under the Banking Act 1959 (Cth). Accordingly, neither DNB Bank ASA nor DNB Carnegie Investment Bank AB is supervised by the Australian Prudential Regulation Authority as an ADI.

DNB Bank ASA is a limited liability company incorporated in Norway.

Nothing in this research report excludes, restricts or modifies a statutory warranty or liability to the extent such an exclusion, restriction or modification would be prohibited under Australian law.

Additional information for clients in Canada

This research report and the information included herein is general investment advice that is not tailored to the needs of any recipient and, accordingly, is distributed to Canadian residents in reliance on section 8.25 of the Canadian Securities Administrators' National Instrument 31-103 Registration Requirements, Exemptions and Ongoing Registrant Obligations. For disclosures regarding any financial or other interest that DNB Bank ASA, DNB Carnegie Investment Bank AB and their affiliates may have in the issuer or issuers that are the subject of this research report please see the potential conflict of interest section and the company-specific disclosures section.

Additional information for clients in Singapore

This research report is distributed by the Singapore Branch of DNB Bank ASA. It is intended for general circulation and does not take into account the specific investment objectives, financial situation or particular needs of any particular person. Please seek advice from a financial adviser regarding the suitability of any product referred to in this research report, taking into account your specific financial objectives, financial situation or particular needs before making a commitment to purchase any such product or security. You have received a copy of this research report because you have been classified as an accredited investor, an expert investor, or as an institutional investor, as these terms have been defined under Singapore's Financial Advisers Act (Cap. 110) ("FAA") and/or the Financial Advisers Regulations ("FAR"). The Singapore Branch of DNB Bank ASA is a financial adviser exempt from licensing under the FAA but is otherwise subject to the legal requirements of the FAA and of the FAR. By virtue of your status as an accredited investor, institutional investor or as an expert investor, the Singapore Branch of DNB Bank ASA is, with respect to certain of its dealings with you or services rendered to you, exempt from having to comply with certain regulatory requirements of the FAA and FAR, including without limitation, sections 34, 36 and 45 of the FAA. Section 34 of the FAA requires a financial adviser to disclose material information concerning designated investment products that are recommended by the financial adviser to you as the client. Section 36 of the FAA requires a financial adviser to have a reasonable basis for making investment recommendations to you as the client. Section 45 of the FAA requires a financial adviser to include, within any circular or written communications in which they make recommendations concerning securities, a statement of the nature of any interest which the financial adviser (and any person connected or associated with the financial adviser) might have in the securities. Please contact the Singapore branch of DNB Bank ASA at +65 6260 0111 with respect to any matters arising from, or in connection with, this research report. This research report is intended for and is to be circulated only to people who are classified as an accredited investor, an expert investor, or an institutional investor. If you are not an accredited investor, an expert investor or an institutional investor, please contact the Singapore Branch of DNB Bank ASA at +65 6260 0111. DNB Bank ASA, its affiliates and subsidiaries, our associates, officers and/or employees may have interests in any products referred to in this research report by acting in various roles including as distributor, holder of principal positions, adviser or lender. DNB Bank ASA, its affiliates, subsidiaries, our associates, officers and/or employees may receive fees, brokerage or commissions for acting in those capacities. In addition, DNB Bank ASA, its affiliates and subsidiaries, our associates, officers and/or employees may buy or sell products as principal or agent and may effect transactions that are not consistent with the information set out in this research report.

Additional information for clients in the United States

The research analyst(s) named on this research report are foreign research analysts as defined by FINRA Rule 1220. The only affiliates contributing to this research report are the investment services division of DNB Bank ASA and DNB Carnegie Investment Bank AB (a wholly owned subsidiary of DNB Bank ASA) ("hereinafter DNB Carnegie"); the foreign research analysts employed by DNB Carnegie are named on the first page; the foreign research analysts are not registered/qualified as research analysts with FINRA; foreign research analysts are not associated persons of DNB Markets, Inc. or Carnegie, Inc. and therefore are not subject to the restrictions set forth in FINRA Rules 2241 and 2242 regarding restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account.

This is a Third Party Research Report as defined by FINRA Rules 2241 and 2242. Any material conflict of interest that can reasonably be expected to have influenced the choice of DNB Carnegie as a research provider or the Subject Company of a DNB Carnegie research report, including the disclosures required by FINRA Rules 2241 and 2242 can be found above.

This research report is being furnished solely to Major U.S. Institutional Investors within the meaning of Rule 15a-6 under the U.S. Securities Exchange Act of 1934 and to such other U.S. Institutional Investors as DNB Markets, Inc. or Carnegie, Inc. may determine. Distribution to non-Major U.S. Institutional Investors will be made only by DNB Markets, Inc. or Carnegie, Inc., separately incorporated subsidiaries of DNB Bank ASA that are U.S. broker-dealers and members of the Financial Industry Regulatory Authority ("FINRA") and the Securities Investor Protection Corporation ("SIPC").

Any U.S. recipient of this research report seeking to obtain additional information or to effect any transaction in any security discussed herein or any related instrument or investment should contact DNB Markets, Inc., 30 Hudson Yards, 81st Floor, New York, NY 10001, telephone number +1 212-551-9800, or Carnegie Inc, 20 West 55th St., New York, NY 10019, telephone number +1 212-262-5800.

At DNB Carnegie, we are dedicated to being the most respected partner for Nordic investment banking and wealth management solutions, leveraging the full capabilities of DNB. With unmatched strength across products, sectors, and geographies, our commitment is crystal clear: Clients first!

We deliver tailored financial solutions in mergers and acquisitions, capital markets, and financial advisory services by leveraging our deep market knowledge and expansive international reach. As an agile investment bank and part of a major Nordic banking group, we offer unparalleled local expertise, exceptional placing power, and a unique network.

Our roots run deep in the Nordic region, with strong local offices in Sweden, Norway, Denmark, and Finland. This solid foundation is amplified by our global presence in London, New York, and Singapore.

DNB Bank ASA
DNB Carnegie
Dronning Eufemias gate 30
0191 Oslo | Norway
Telephone: +47 915 04800

www.dnb.no

DNB Carnegie Investment Bank AB

Regeringsgatan 56
103 38 Stockholm | Sweden
Telephone: +46 8 676 88 00

www.dnbcarnegie.se

DNB Carnegie Investment Bank, Denmark Branch
Overgaden neden Vandet 9B PO Box 1935
1414 Copenhagen K | Denmark
Telephone: +45 32 88 02 00

DNB Bank ASA, Singapore Branch
DNB Carnegie
1 Wallich Street Downtown Core 06
#30-01, Guoco Tower,Singapore 078881
Telephone: +65 6260 0111

DNB Carnegie Investment Bank AB, Finland Branch
Eteläesplanadi 2 PO Box 36
FI-00131 Helsinki | Finland
Telephone: +358 9 618 71 230

DNB Bank ASA, London Branch
DNB Carnegie
The Walbrook Building, 25 Walbrook
London EC4N 8AF | England
Telephone: +44 20 7216 4000

DNB Carnegie Investment Bank AB, UK Branch
Finwell House, 26 Finsbury Square
London EC2A 1DS | England
Telephone: +44 20 7216 4000

DNB Markets, Inc.

30 Hudson Yards
New York, NY 10001 USA
Telephone: +1 212 551 9800

Carnegie, Inc.

20 West 55th St.
New York N.Y. 10019
Telephone: +1 212 262 5800